2022
SDI
Disadvantage
Food Innovation DA › 2NC › 2NC---Biotech Links
Joseph Pategou, 3-19-2019, Joseph Pategou is a consultant with the management consulting firm Wavestone, specialized in the pharmaceutical industry. He has published more than 20 articles and completed a Master of Sciences in International Strategy and Influence, as well as a master’s in chemistry and life sciences. "The Marriage of Big Pharma and Biotech", Drug Discovery and Development, https://www.drugdiscoverytrends.com/the-marriage-of-big-pharma-and-biotech/, 7-3-2022, //ms
In 2017, the worldwide pharmaceutical market reached 1 trillion Euro, an increase of 6.7 percent over 2016. This market is expected to continue to growth at 4 percent CAGR and exceed 1.1 trillion euros by 2020. Four main growth drivers are behind this evolution, which occurred in spite of bad and challenging market conditions—growing health spending in emerging countries, drug price increases in some key markets, growing demand for generics in a context of high patent expiries, and innovative drugs and new treatments, especially in the field of oncology, which accounted for 27 percent of active global R&D pipelines in 2017, ahead of neurology and virology. For decades, pharmaceutical companies have been bringing innovative drugs to market for the benefit of the patients and the society. However, this process is not straightforward. The average time for a new drug to reach the market is between eight and 12 years. On average, from 10,000 compounds at the discovery phase, only one is approved and reaches the market. With more than 14 percent of its revenues allocated to R&D, the pharmaceutical industry is a leading contender in terms of R&D spending. From 2007 to 2016, the industry invested more than $1.3 trillion in R&D and forecasts predict an annual investment of $204 billion by 2024, with the U.S. leading the pack. This huge investment in R&D is necessary for pharmaceutical companies to launch new drugs, to sustain growth and profit. However, in recent years declining productivity has become a concern for pharmaceutical companies. R&D returns declined to 2 percent in 2018, down from 10 percent in 2010, with figures showing a steady decline. Moreover, during the past decades, the average drug development costs has been multiplied by more than 13, from 160 million euros in 1970 to 2.3 billion in 2010. This evolution is due to many factors, such as higher technical, regulatory and economic constraints, but also the search of innovative drugs by companies facing competition. For many experts, this situation raises questions on the capacity of the industry to innovate and to create growth in the future. Furthermore, 160 drugs lost patents in recent years, and this number is expected to reach more than 40 between 2017 and 2020. The new landscape opens the door to generic and biosimilar drugs and creates more opportunity for more competition, between existing players and new ones. New business models This situation has a big impact on the big pharmaceutical blockbuster business model, which is based on top selling drugs that generated over 1 billion USD in annual sales. Large pharmaceutical companies are changing and adapting their capabilities by focusing on external growth, more precisely mergers and acquisitions (M&A), to increase R&D capabilities and boost portfolio with biotech companies as preferred targets. In the past 10 years, merger and acquisition activities have significantly increased, with a high in 2015 when the total value reached more than 345 billion USD. 2019 started with the same strength, a mega merger between Bristol-Myers Squibb and Celgene of 95 billion USD (including debt recovery)—an astronomical amount which confirms the growing interest in biotech. Beyond M&A, partnerships with biotech companies are also appealing to big pharmaceutical companies. We have observed an increase in partnerships between biotech companies and pharmaceutical companies as a way to feed their pipeline and minimize risks and costs. For example, through a strategic partnership, Genentech and AbbVie developed Venclexta, an oncology drug. It is jointly commercialized by Genentech in the United States and commercialized by AbbVie outside of the United States. Big pharmaceutical companies are looking at biotech companies for many reasons. First, biotechnology companies clearly dominate new drug pipelines. Secondly, they are characterized by a very specific know-how and high value-added research involving patented technologies. They participate strongly in therapeutic innovation and are structures of interest for large pharmaceutical companies. Finally, biotech companies can bring more efficiency and responsiveness through licensing agreements to pharmaceutical companies. Put all together, biotech startups can help pharmaceutical companies to strengthen and revitalize portfolios in a challenging landscape where innovation is key. At the same time large companies bring financial support and expertise to put drugs on the market through enhancement of clinical development, market access and regulatory affairs. This strategic shift by large pharmaceutical companies toward biotech through M&A and partnering is bearing fruit. During the past 10 years, the number of new molecular entities has increased steadily. In 2018, the European Medicines Agency (EMA) had approved 84 (vs 94 in 2017) new drugs with 42 (vs 35 in 2017) of these being new active substances. At the same time, the U S Food and Drug Administration (FDA) had approved 59 novel drugs and biologics in 2018 (vs 46 in 2017). Moreover, biotechnology drugs are contributing to sales at a large scale. For EvaluatePharma, these products will represent 31 percent of the market in 2024 in comparison to 25 percent in 2017. This heavy role played by biotech companies is more visible when the top 100 products sales are put in the spotlight; biotech drugs are predicted to account for 52 percent of sales in 2024 (vs 49 percent in 2017). Based on this forecast, the dependency of the industry on biotech is clear. In this landscape, Roche has a leading position build through continued investment, the acquisition of Genentech, a biotechnology pioneer, in 2009 for $46.8 billion or Ignyta, a biotech in oncology, for $ 1.7 billion in 2017 in order to foster the company’s position in oncology. A new strategic roadmap Biotechnology companies can be a strategic pillar to help pharmaceutical giants redesign themselves. In the past decades, many groups have been defining a new strategic roadmap from diversification strategy to focus on core areas. In the case of Sanofi, the company is remaining on a diversification strategy, but started since 2016 restructuring a plan and discarded non-strategic activities. Sanofi sold its animal health business (Merial) and withdrew from some of its generic business by selling its subsidiary Zentiva, which manufactures generic drugs for the European market. In order to position itself on the strategic areas of oncology, immunology and multiple sclerosis, Sanofi have been using external growth strategy. Between 2017 and 2018, Sanofi bought three biotechnology companies, which allow it to reinforce its presence in the specialty medicine landscape. The first was Protein Sciences in 2017 for $750 million, through the acquisition of the biotech, Sanofi Pasteur, the vaccines global business unit of Sanofi. This adds a promising product, based on recombinant proteins, to its influenza vaccine portfolio. The second acquisition is Ablynx, a Belgian biotech company for $4.8 billion. Ablynx is engaged in the development of nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx has more than 45 proprietary and partnered programs in development in various therapeutic areas, including inflammation, hematology, immuno-oncology, oncology and respiratory disease. Finally, Sanofi purchased Bioverativ for $11.6 billion, a U.S. biotech company focusing on therapies for hemophilia and other rare blood disorders. This acquisition should have two upsides or benefits—it helps Sanofi build a leading hemophilia portfolio and strengthens Sanofi’s portfolio in specialty care. The decline in R&D productivity, the increase in costs of drugs, the tough competition between existing and new players, and expertise of biotech companies has created an undeniable and undisputable incentive for a marriage between big pharma and biotech companies. Even if, the path to success is not guaranteed, the opportunity need to be taken for a brighter and exciting future for patients, large pharma players and in the end, creation of shareholder value.
2022
SDI
Disadvantage
Food Innovation DA › 2NC › 2NC---Biotech Links
, Apr 5, 2022, Annalee Armstrong is a senior editor for Fierce Biotech. Prior to joining Fierce in April 2021, Annalee was an associate editor for S&P Global Market Intelligence’s healthcare news team. Before that, she was the EPA reporter covering climate and energy policy on the Hill in Washington, D.C. Annalee got her start in journalism at daily newspapers across Western Canada chasing sled dogs and other stories. In her free time, Annalee enjoys yoga, camping and exploring the Blue Ridge Mountains from her home base in Charlottesville, Virginia. "Big Pharma partnerships, record $22.7B investment raise profile of regenerative medicine in 2021", https://www.fiercebiotech.com/biotech/big-pharma-partnerships-record-investment-raise-profile-regenerative-medicine-2021, 7-3-2022, //ms
Regenerative medicine couldn't stop making news in 2021. The year was marked by Intellia's for gene editing, massive Big Pharma partnerships and record investment of $22.7 billion. This past year saw six new cell, gene and tissue-based therapies approved, according to an from the Alliance for Regenerative Medicine (ARM). Meanwhile, CAR-T therapies put up the data to justify moving up a line in cancer treatment, and venture capital went all-in on the field. Some major milestones for the field are yet to come in 2022, ARM said. About nine therapies are awaiting FDA nods, and another seven are before EU regulators. They include Gamida Cell’s cell therapy omidubicel and BioMarin’s ValRox for hemophilia A. For 2023, two sickle cell disease treatments, bluebird bio’s gene therapy and CRISPR Tx and Vertex Pharmaceuticals’ , will be considered in the U.S. Pharmaceutical drug developers continue to realize the strong therapeutic potential of highly potent active pharmaceutical ingredients (HPAPIs). This is particularly true for therapeutic areas such as oncology, where highly potent drugs are becoming more commonplace. Download this Executive Summary to learn more about Catalent's approach on safe handling procedures and effective formulation strategy. There was much debate over delivery mechanisms for gene therapies, which ARM said weighed down the field in 2021. But the group, an advocacy organization with more than 425 members, is optimistic that the field is making progress in finding new ways to optimize the leading mechanism, adeno-associated viruses. ARM also noted that the FDA has indicated it will not impose a universal dose cap on AAV-based gene therapies. AAVs were used in 145, or 46% of all gene therapy clinical trials. Other mechanisms included lentivirus, which had 24 clinical trials, or 8%, and adenovirus, with 22, or 7% of trials. Gene editing had 41 trials underway this past year, with one-third in phase 1 and the rest in phase 2. About 80% of these use . That includes Intellia’s transthyretin amyloidosis treatment that had a much buzzed about readout in summer 2021. The company rolled out from the study in February that showed a dose-dependent response and began to answer the durability question associated with gene editing. More than half of all gene editing trials are in cancer. 2021 also saw the first gene editing therapy in a more common disease, when CRISPR Tx and ViaCyte launched a study in Type 1 diabetes. As for investment, gene therapy and cell-based companies nabbed the majority of funds at $10.2 billion and $10.1 billion, respectively. Cell therapy followed with $2 billion and tissue engineering biotechs garnered $341 million. The majority of the cash came from venture capital, which contributed $9.8 billion—a 75% increase over the year before. IPOs helped companies raise $4.8 billion, an increase of 30%. There’s been a rush of Big Pharma partnerships across biotech, and these deals helped raise $2.3 billion through upfront payments in 2021, a 23% increase year over year. ARM noted the $900 million upfront payment Vertex offered to CRISPR Tx to work on CTX001 and AbbVie’s $370 million check for for an eye disease gene therapy. Cancer is easily the busiest indication for regenerative medicine, with a whopping 1,246 trials underway right now across oncology, or 52% of all studies in the field globally. The sector has long been working on hematological cancers, which saw 685 trials, or 55%. But ARM noted a shift over the past year toward solid tumors, which climbed to 561, or 45% of trials. Gastrointestinal cancers were the leading indication here, with 130 trials, or 23% of all solid tumor trials underway, followed by brain and spinal cord cancers with 71 or 13%. CAR-T therapies also moved up a treatment line this past year, with both Gilead Sciences and Bristol Myers Squibb reporting data showing their therapies performed well against second-line standard of care in relapsed or refractory large B cell lymphoma.
2022
SDI
Disadvantage
Food Innovation DA › 2NC › DA turns case
Stockholm International Peace Research Institute, 19, (Stockholm International Peace Research Institute, 3-27-2019, 8-16-2021, World Economic Forum, < https://www.weforum.org/agenda/2019/03/how-emerging-technologies-increase-the-threat-from-biological-weapons/ > Blucas
The main conclusion is that, while new developments in these three emerging technologies could have an enabling effect in different steps of the development and use of biological weapons, the existing governance frameworks are ill-equipped to comprehensively address these risks. To improve the ability to govern the convergence of biotechnology with other emerging technologies, concrete steps could be taken by national governments, regional organizations such as the European Union (EU) and international institutions, and by academia, the private sector and the DIY community. National governments should more systematically assess technological developments, map domestic stakeholders, make use of parliamentary assessment mechanisms, increase resources for relevant authorities, and strengthen research on the detection, prevention, response and attribution of biological incidents. The EU should enhance engagement with the biotechnology industry and biosafety associations in the context of dual-use risks. The BTWC regime should reform some of its elements, including its working practices and stakeholder engagement, and create a BTWC Scientific Advisory Board. It could also raise the issue of convergence on its agenda and better address the potential for misuse of commercial biotechnology and emerging technologies. Academic institutions should introduce obligatory courses on ethics, law and biosafety in all natural science curriculums, encourage work on interdisciplinary technology assessments and further strengthen the collaboration between national academies of sciences, particularly on addressing risks resulting from technological convergence. The private sector should continuously strengthen its self-governance and compliance standards. The DIY community could organize workshop series on biosecurity for community laboratories and strengthen international efforts to foster responsible science and biosecurity awareness.
2022
SDI
Disadvantage
Food Innovation DA › 1NC
Ore Koren, 16, (Ore Koren, Ore Koren is a PhD candidate at the University of Minnesota and a Jennings Randolph Fellow at the United States Institute of Peace., 11-23-2016, Washington Post, Food scarcity causes conflicts — but so can food abundance. Here’s why., https://www.washingtonpost.com/news/monkey-cage/wp/2016/11/23/food-scarcity-causes-conflicts-but-so-does-food-abundance-heres-why/, 6-28-2021) SCade
For a new U.S. administration facing global security challenges, the relationship between food security — what the World Bank defines as “access to enough food for an active, healthy life” — and armed conflict deserves serious consideration. As new research shows, even an abundance of food resources can cause conflict. Recent studies theorize that in Syria, where an estimated 250,000 to 400,000 people have died since 2011, the drought that preceded the civil war played a significant role in fueling political tensions. Increases in food prices caused by drought were also a factor in the 2011 Arab Spring uprisings in Tunisia, Jordan, Yemen and Egypt. The fact that prolonged food shortages can lead to drastic, violent behavior is becoming increasingly evident. The relationship between food and war is both complex and multidimensional, though. The links between food scarcity and war Warmer countries are more war-prone — that’s what researchers studying the relationships between environmental factors and civil war argue. As global temperatures increase, prolonged heat waves reduce crop yields. The impact is strongest in tropical regions, which are more likely to experience the harshest effects of global warming. Lower crop yields increase the competition for remaining crops. And rising prices mean that many people cannot afford to buy food to compensate for resources lost because of climatic shifts. In countries that lack a social “safety net,” the only alternative in many cases is to obtain food through stealing, looting and — frequently — fighting over fertile land. Anecdotal evidence from eastern Africa and the Middle East, at least, supports this theory. Attempts to measure the linkages between climate change and armed conflict, however, have yielded mixed results, with some studies at least partly reaffirming these connections and others debunking them. Some regions adapt to climate conditions better than others Studies of the “Green Revolution” movement of the 1960s suggest that regions such as Asia were far more successful than Africa at adopting drought-resistant crops, which improved food security and helped offset the risk of war. Similar efforts in sub-Saharan Africa and the Middle East were weak and generally unsuccessful until the late 1980s. These efforts met with limited success because of the types of grain available and other socioeconomic complexities, which left these regions food insecure. Had Syria successfully adopted drought-resistant crops, for instance, the social unrest of 2011 might have taken a different, less-violent course. As researchers continue to debate how climate change and its effects on global food stocks will impact food security in future decades, short-term environmental “shocks” such as droughts or floods have become more frequent in many parts of the world and are a potentially salient cause of armed conflict. These environmental disturbances can lead to sharp price increases that, in turn, can cause another well-established tradition: the food riot, when civilians take to the streets to protest high food prices. Low-income countries are particularly susceptible because high food prices in these situations have an especially destabilizing effect. In these countries, high food prices expose the government’s lack of ability to shield consumers. They also create opportunities for civilians to mobilize against the regime. Even in locations where food is sourced locally, drought-induced shocks may incite violence against civilians when rebel groups seek to appropriate local food supplies. My research documents this happening not only in the Syrian conflict but also in India and Thailand during a 2004 drought. Riots, protests and massacres are among the types of unrest that can lead to civil war — and all can be linked to food conflicts.
2022
SDI
Disadvantage
Food Innovation DA › 1NC
Elsevier, 14, (Elsevier, 2014, Elsevier, The agrochemicals industry takes on climate change https://www.elsevier.com/?a=196459, 6-25-2021) SCade
Food Shortage Fears Frustratingly, climate change threatens to damage and lessen the planet’s food supply at a time when we need more food than ever. The worldwide population continues to explode, meaning that it’s not just about protecting the current supply, but also being prepared to grow it substantially to meet an ever-greater global demand. The United Nations has declared that food production must double by 2050 in order to feed the burgeoning population, one billion of whom are already suffering from hunger. This is a concern that is raised again and again among those working in agrochemicals, who feel a great responsibility to see their industry meet this vital need. Biotech to the Rescue “I’m a big believer in biotech and the doors that it can open,” says Madden, who was working at Asgrow (a seed company owned by Monsanto) when the first biotechnology products were introduced in the 1990s. “Humanity is dependent on crop breeding in combination with biotechnology to keep up with climate change.” Advances in biotechnology have made it possible to genetically modify crops with traits that make them resistant to pests and diseases. This not only helps farmers fight off problems that may result from climate change, but it also means that they contribute less to it themselves. Why? When farmers get better yields, they need less land to grow on – therefore slowing deforestation and the greenhouse gas emissions that come with it. And there is so much more that biotech could do to actively fight climate change. In a piece in The Berkeley Blog, author David Zilberman suggests that one such innovation could be to make GM soybean crops with improved digestibility, so that the cattle eating them release fewer greenhouse gases. Researchers are working on biotechnology that could solve any number of problems related to climate change, but it can be a long and arduous process of trial and error, as they attempt to find effective solutions. GM crops that are resistant to drought, for example, would be a godsend for farmers, but Madden explains that though “drought tolerance has been worked on for quite a while, early gene products have been somewhat disappointing to companies based on what is offered and achieved. ”He points out that regional differences in rainfall and soil type, as well as climate shifts, can complicate matters.
2022
SDI
Disadvantage
Food Innovation DA › 1NC
Claire O’Connell, 11-14-2019, Claire O'Connell is a contributor to The Irish Times who writes about health, science and innovation "Why gene editing is decade’s most significant innovation", Irish Times, https://www.irishtimes.com/business/innovation/why-gene-editing-is-decade-s-most-significant-innovation-1.4080666, 6-28-2022, //ms
gene editing (like the other innovations) has been in the works for a while, the last seven years have seen major developments in our ability to specifically edit DNA in living cells. It is not without controversy. Recent claims that human embryos in China had been genetically edited and had resulted in twin babies prompted widespread condemnation from scientists, as well as discussions about safety and ethics and calls for effective regulation. But as a technology, the ability to alter a gene in a living cell offers many potential benefits, including treating inherited diseases, understanding what specific genes do, generating more resilient crops and even detecting species in the environment. "The field is amazing," says Jane Farrar, a professor of genetics at Trinity College Dublin. "I have had some very late nights updating my lecture slides for undergraduates, because so much in gene technology is happening so quickly." Gene editing – which directly changes the “letters” of the genome – is becoming more of a feature of gene therapy, notes Farrar, but it is the new kid on the block. “The ability to edit specific genes in living cells is relatively new,” she says. “That means many forms of gene therapy that have by now reached the clinic or are under late-stage development don’t use these new gene-editing techniques. They deliver the gene into the cell, rather than correcting or editing the DNA,” she notes. Farrar was one of the pioneers of gene therapy research in Ireland in the 1980s and 1990s, when the patient-led charity Fighting Blindness supported work to find the genetic changes linked to inherited forms of vision loss. “The eye is really an ideal place for gene therapy,” she explains. “It is accessible, it can tolerate the viruses used to deliver genes and you have a natural control – if you put the gene therapy in one eye you can compare it to the other over time.” Rare eye disease Farrar, Prof Pete Humphries and colleagues identified gene changes involved in a rare eye disease called retinitis pigmentosa, and developed a system to "rescue" the gene function by suppressing the mutant gene and delivering a new gene into the cell. The technology was acquired by Spark Therapeutics in 2016. In 2017, the FDA in the USA approved a different Spark therapy, Luxturna, which replaces the function of gene changes associated with progressive sight loss. It was the first gene therapy of its kind to be approved in the US. “In general, there’s a huge amount of commercial interest in new gene therapies,” says Farrar. “Plenty more are in the works, not just for inherited eye diseases but also for rare diseases that affect how cells break down cellular components to recycle them, conditions that damage the mitochondria [which act as “batteries” in cells] and spinal and central nervous system disorders, among others.” She believes that gene editing will become more common in gene therapy approaches in the coming years, particularly as we work out how to do it safely and effectively. “With gene editing, there is the potential risk of ‘off-targets’, where editing a target gene could bring about unintentional changes in the genome or cell function, so some researchers are looking for ‘safe harbours’ in DNA,” she explains. “These are stretches of DNA where in principle you could add different genes targeting different disorders, while avoiding negative off-target effects.” The availability of gene editing in recent years also means that scientists can now use it as a research tool to target specific stretches of DNA relatively easily, according to Prof Breandan Kennedy, a senior lecturer at University College Dublin. Probably the best known gene-editing technology is CRISPR-Cas9, which was made commercially available in 2012. A little like having a sat-nav and a scissors, CRISPR-Cas systems allows you target a specific sequence of DNA “letters” in a living cell, then cut the sequence at that point. ‘Very powerful’ “By doing this, we can inactivate a specific gene, and this gives us a lot of information about what that gene normally does,” says Kennedy, whose work at UCD school of biomolecular and biomedical science uses gene editing technology on microscopic worms, zebrafish and human cells in the lab. “By inactivating specific genes, which we can do much more quickly and easily now with CRISPR-Cas systems, our group has been able to identify genes that are important for vision, for eye development and for blood vessels in the eye to grow and work properly. We are also using the approach to validate in the lab whether particular DNA change in patients are involved in inherited eye disease. Ten years ago if you said such a technology would be widespread, people would have laughed, but now labs around the world can do this. It’s very powerful.” Plant science, too, is reaping the rewards of being able to target specific stretches of DNA in living cells. "What is possible now is what was impossible five years ago," says Dr Ewen Mullins, head of the crop science department at Teagasc, Oak Park. “The holy grail for plant breeding is to be able to control the activity of a single gene, or several linked genes, and now gene editing allows us to do that,” he says. “And crucially, we are not necessarily adding a gene in from another species. With CRISPR-Cas systems, we can edit the genes already in the plant.” This could help to make crop plants more resilient in the face of droughts, fluctuating temperatures and agents of disease, notes Mullins: “These are becoming issues for farmers in Ireland and other parts of the world now, and in the face of climate change we need to reduce those susceptibilities where we can into the future.” Identifying species Gene-editing technology can even help us to identify what species are living in a particular environment, as Dr Anne Parle-McDermott from Dublin City University is finding out. "We are looking at the different species of salmon that live in rivers and aquaculture, but we are doing that by analysing the DNA they shed, also known as environmental or e-DNA," she explains. "We can take a sample of water, then we add CRISPR to find unique stretches of DNA that tell us about the species it came from. The associated Cas protein then cuts a reporter DNA and we can detect that cutting activity, so we know that stretch of DNA is present in the sample. It gives us a whole new way of knowing what DNA is present in the environment." Dr Ciaran Seoighe, deputy director general at Science Foundation Ireland, is impressed that gene technology won the reader vote for the innovation of the decade. "CRISPR-Cas9 is a case of a discovery turned into an innovation," he says. "Decades ago, researchers were discovering that bacteria had this system of being able to find and cut DNA in viruses and so stop them attacking, and the innovation was to take that and use it to specifically edit genes ourselves. It was a case of finding something interesting and then doing something different with it. Now it provides a tool for researchers to work on more personalised approaches to medicine." Farrar is also impressed by the winning vote. “I think the readers are very insightful,” she says. “Gene technology has matured in the last decade, and thanks to gene-editing technology we can also now get far more understanding about disease. This is really a story of fundamental biology enabling a new technology. Without that curiosity, we might not have these exciting innovations now.”
2022
SDI
Disadvantage
Food Innovation DA › 1NC
Data Journalism Team, 22, (Data Journalism Team, The data journalism team works across GlobalData's media portfolio, providing data driven analysis from the company's proprietary datasets., 3-21-2022, Pharmaceutical Technology, North America is seeing a hiring boom in pharmaceutical industry big data roles, https://www.pharmaceutical-technology.com/analysis/north-america-is-seeing-a-hiring-boom-in-pharmaceutical-industry-big-data-roles/, 7-2-2022) SCade
North America extended its dominance for big data hiring among pharmaceutical industry companies in the three months ending January. The number of roles in North America made up 64% of total big data jobs – up from 59.7% in the same quarter last year. That was followed by Asia-Pacific, which saw a -0.9 year-on-year percentage point change in big data roles. The figures are compiled by GlobalData, who track the number of new job postings from key companies in various sectors over time. Using textual analysis, these job advertisements are then classified thematically. GlobalData's thematic approach to sector activity seeks to group key company information by topic to see which companies are best placed to weather the disruptions coming to their industries. These key themes, which include big data, are chosen to cover "any issue that keeps a CEO awake at night". By tracking them across job advertisements it allows us to see which companies are leading the way on specific issues and which are dragging their heels - and importantly where the market is expanding and contracting. Which countries are seeing the most growth for big data job ads in the pharmaceutical industry? The fastest growing country was the United States, which saw 57.6% of all big data job adverts in the three months ending January 2021, increasing to 61.4% in the three months ending January this year. That was followed by India (up 1.9 percentage points), Canada (0.5), and the United Kingdom (-0.199999999999999). The top country for big data roles in the pharmaceutical industry is the United States which saw 61.4% of all roles advertised in the three months ending January.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › China War defense
Tim Huxley 18, Executive Director, International Institute for Strategic Studies (Asia) Ltd, 9-12-2018, "Why Asia's 'arms race' is not quite what it seems," World Economic Forum, https://www.weforum.org/agenda/2018/09/asias-arms-race-and-why-it-doesnt-matter/
Increased military spending and arms purchasing by regional countries are often identified as key indicators of a deteriorating regional security predicament. Almost as a reflex, some commentators point to the growing dangers of a supposed Asian ‘regional arms race’; this piece from the South China Morning Post is typical. There is a widespread impression that regional states’ escalating military spending and reckless development of offensive military capabilities are increasing the risk of conflict. Closer examination, though, reveals that the hard evidence of military developments in the region does not come close to the intense bilateral rivalry and speed of classic arms races involving major offensive capabilities, such as the contest for naval superiority between Great Britain and Germany at the start of the twentieth century, or that between the US and the Soviet Union for strategic nuclear superiority in the 1950s and 1960s. As shown in this graphic illustrating International Institute for Strategic Studies (IISS) figures on defence spending in what American officials and others increasingly refer to as the ‘Indo-Pacific region’, China is a long way from competing with the US in terms of military effort. At the same time, no other regional state comes close to competing with China. And while many Asian governments are increasing their defence spending at quite a rate, they are mainly doing this commensurately with their economic growth, which has been famously rapid for most of the current century. This graphic – also using IISS figures - focuses on Southeast Asian states’ military efforts as a percentage of GDP over the last 25 years, but a similar picture of defence effort shadowing economic growth is apparent across Asia. Many factors go into the formation of defence policy and levels of defence spending by Asian governments, but it seems clear that the sheer availability of greater resources is an important one. And regional states do not, apparently, generally feel compelled to increase their defence efforts more quickly than their economies are growing. Media reports often highlight expensive arms purchases by Asian governments. But military capability is complex, and buying new ‘kit’ does not provide countries with instant capabilities, as is often inferred. Other important elements of capability include appropriate doctrine, suitable training, inspiring leadership, high morale, vital logistic support (including defence-industrial capacity), relevant combat experience and a high level of operational integration between military branches and services. Besides, mastery of the cyber domain may be emerging as the sine qua non of military capability, potentially providing the capacity to take down an opponent’s ability and will to fight even before a shot is fired. Only a minority of Asian armed forces possess all these key capability elements. In many cases, while they might be able to hold domestic insurgents or other forms of unrest at bay, or engage in border skirmishes, their forces would be unable to mount sustained operations against those of other countries. Moreover, most of the military capabilities under development in the region remain essentially defensive. This applies not least to China’s People’s Liberation Army (PLA). China’s major, sustained, long-term defence effort is certainly enhancing the capabilities of the PLA, which would in any conflict now be able to complicate US operational planning and activities severely. But China’s long-range offensive capabilities – its nuclear deterrent aside - remain limited. The PLA is still a long way from matching American capabilities, and it would have little hope of winning any conflict with the US, whose military presence and commitments continue to ensure the security of the whole region.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › China War defense
Coco 20 – Orazio, Visiting lecturer at U of Hong Kong, where he earned an MA in International affairs, Ph.D in History of Europe (summa cum laude) from Sapienza University of Rome. “Contemporary China and the “Harmonious” World Order in the Age of Globalization”, Chinese Journal of Global Governance, , 04-06-2020
The question is whether China would risk losing its achievements and recognition of being part of the international leadership for a relevant ‘domestic’ matter of geographical territory. The answer can be found in history. Waging war does not bring popularity or more power. Conflicts do not bring progress and prosperity and certainly not a leadership role for the countries leading their nations to destruction and human losses. Europe has inexorably withdrawn from being an important geopolitical and military global leader after initiating and staging two World Wars. History has also taught us that the moral quality of leadership is the most qualified reassurance that discourages wars. In the age of nuclear powers such as China and the United States, the consequences of a conflict will be devastating for humanity, and they will be worse for the ideal process of progress and advancement of the involved nations. As far as China is concerned, as Chan argues, all the previously mentioned risks and weaknesses suggest that the current Chinese strategy does not seem to be one of a rising world hegemon but that of a strong country searching for a regional (Asian) leadership role rather than being an impatient newcomer determined to challenge or change the existing international order. 5 More Considerations about the Harmonious International (Socialist) Order As so far argued, China’s political role and economic relevance are strongly linked to the achievement of the ‘harmonious’ and peaceful global order. The fact that the entire idea of a ‘Great China’ is built on the fundamental assumption that only a world at peace can bring prosperity for the Chinese nation and give recognition to China as an important power in international society should not be underestimated. The emergence in the world of any kind of conflict that affects international political instability and economic volatility in the international markets does not support the long-term consolidation of the socio-economic results achieved by China in recent years. This awareness of the need for peace and harmony guides Chinese leadership in pursuing consistent policies in domestic and international affairs. Achieving this goal requires ‘orderliness’, that is, national and international order must be maintained and protected.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › China War defense
Charles C. Krulak & Alex Friedman 21, former President of Birmingham-Southern College, former Commandant of the US Marine Corps, M.S. from George Washington University; former Chief Financial Officer of the Bill & Melinda Gates Foundation, J.D. from Columbia University, “The US and China Are Not Destined for War,” Project Syndicate, 08-17-2021, https://www.project-syndicate.org/commentary/us-china-not-destined-for-war-by-charles-c-krulak-and-alex-friedman-1-2021-08
True, throughout history, when a rising power has challenged a ruling one, war has often been the result. But there are notable exceptions. A war between the US and China today is no more inevitable than was war between the rising US and the declining United Kingdom a century ago. And in today’s context, there are four compelling reasons to believe that war between the US and China can be avoided.
First and foremost, any military conflict between the two would quickly turn nuclear. The US thus finds itself in the same situation that it was in vis-à-vis the Soviet Union. Taiwan could easily become this century’s tripwire, just as the “Fulda Gap” in Germany was during the Cold War. But the same dynamic of “mutual assured destruction” that limited US-Soviet conflict applies to the US and China. And the international community would do everything in its power to ensure that a potential nuclear conflict did not materialize, given that the consequences would be fundamentally transnational and – unlike climate change – immediate.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › Warming defense
Zing Tsjeng, 19, 2-27-2019, executive editor and the author of the Forgotten Women book series, "The Climate Change Paper So Depressing It's Sending People to Therapy", [https://www.vice.com/en_us/article/vbwpdb/the-climate-change-paper-so-depressing-its-sending-people-to-therapy], AVD
"Deep Adaptation" is quite unlike any other academic paper. There's the language ("we are about to play Russian Roulette with the entire human race with already two bullets loaded"). There's the flashes of dark humor ("I was only partly joking earlier when I questioned why I was even writing this paper"). But most of all, there's the stark conclusions that it draws about the future. Chiefly, that it's too late to stop climate change from devastating our world—and that "climate-induced societal collapse is now inevitable in the near term." How near? About a decade. Professor Jem Bendell, a sustainability academic at the University of Cumbria, wrote the paper after taking a sabbatical at the end of 2017 to review and understand the latest climate science "properly—not sitting on the fence anymore," as he puts it on the phone to me. What he found terrified him. "The evidence before us suggests that we are set for disruptive and uncontrollable levels of climate change, bringing starvation, destruction, migration, disease, and war," he writes in the paper. "Our norms of behavior—that we call our 'civilization'—may also degrade." "It is time," he adds, "we consider the implications of it being too late to avert a global environmental catastrophe in the lifetimes of people alive today." Even a schmuck like me is familiar with some of the evidence Bendell sets out to prove his point. You only needed to step outside during the record-breaking heatwave last year to acknowledge that 17 of the 18 hottest years on the planet have occurred since 2000. Scientists already believe we are soon on course for an ice-free Arctic, which will only accelerate global warming. Back in 2017, even Fox News reported scientists' warnings that the Earth's sixth mass extinction was underway. Erik Buitenhuis, a senior researcher at the Tyndall Centre for Climate Change Research, tells me that Bendell's conclusions may sound extreme, but he agrees with the report's overall assessment. "I think societal collapse is indeed inevitable," he says, though adds that "the process is likely to take decades to centuries." The important thing, Buitenhuis says, is to realize that the negative effects of climate change have already been with us for some time: "Further gradual deterioration looks much more likely to me than a disaster within the next ten years that will be big enough that, after that, everybody will agree the status quo is doomed." "Jem's paper is in the main well-researched and supported by relatively mainstream climate science," says Professor Rupert Read, chair of the Green House think-tank and a philosophy academic at the University of East Anglia. "That's why I'm with him on the fundamentals. And more and more people are." Read's key disagreement with Bendell is his belief that we still have time to snatch victory from the jaws of defeat, saying, "I think it's hubris to think that we know the future." But that doesn't mean Bendell's premise is wrong: "The way I see it, deep adaptation is insurance against the possibility—or rather, the probability—of some kind of collapse," says Read. "'Deep Adaptation' is saying, 'What do we need to do if collapse is something we need to realistically plan for?'" When I speak to Bendell, he tells me he thinks of "Deep Adaptation" as more of an ethical and philosophical framework, rather than a prophecy about the future of the planet. "The longer we refuse to talk about climate change as already here and screwing with our way of life—because we don't want to think like that because it's too frightening or will somehow demotivate people—the less time we have to reduce harm," he says with deliberation. What does he mean by harm? "Starvation is the first one," he answers, pointing to lowering harvests of grain in Europe in 2018 due to drought that saw the EU reap 6 million tons less wheat. "In the scientific community at the moment, the appropriate thing is to say that 2018 was an anomaly. However, if you look at what's been happening over the last few years, it isn't an anomaly. There's a possibility that 2018 is the new best case scenario." That means, in Bendell's view, that governments need to start planning emergency responses to climate change, including growing and stockpiling food. He minces his words even less in his paper: "When I say starvation, destruction, migration, disease, and war, I mean in your own life. With the power down, soon you won't have water coming out of your tap. You will depend on your neighbors for food and some warmth. You will become malnourished. You won't know whether to stay or go. You will fear being violently killed before starving to death." Should people start building bunkers and buying bulletproof vests? "There's no way of getting through this unless we try together," he says. "We need to help people stay fed and watered where they live already to reduce disruption and reduce civil unrest as much as we can." Of the Silicon Valley financiers prepping for the apocalypse in New Zealand, he says: "Once money doesn't matter anymore and the armed guards are trying to feed their starving children, what do you think they'll do? The billionaires doing that are just deluded." Bendell wasn't always this gloomy about the state of the world. He once worked for WWF, one of the biggest environmental charities in the world, and in 2012 founded the Institute for Leadership and Sustainability (IFLAS) at the University of Cumbria. The World Economic Forum named him a Young Global Leader for his work. So how did he end up writing a paper that determined that civilization—and environmental sustainability as we currently understand it—is doomed? "Since the age of 15, I've been an environmentalist," he tells me. "I've given my life professionally and personally. I'm a workaholic, and it was all about sustainability." Once he sat down with the data, however, he realized that his field was quickly becoming irrelevant in the face of oncoming climate catastrophe. "It would mean not getting super excited about the expansion of your recycling program in a major multinational," he says. "It's a completely different paradigm of what we should be looking at." What he didn’t expect was for the paper to take off online. "It was aimed at those people in my professional community and why we're in denial," he says. "When I put it out there, I didn’t expect 15-year-olds in schools in Indonesia to be reading it with their teachers." He says that "Deep Adaptation" has been downloaded over 110,000 times since it was released by IFLAS as an occasional paper. "Someone in the alternative economics and bitcoin crowd told me, 'Oh, everyone's talking about deep adaptation in London at all the dinner parties,'" he laughs. Researchers from the Institute for Public Policy Research (IPPR), an established progressive think-tank, consulted Bendell's paper in the process of writing its new report, "This is a crisis: Facing up to the age of environmental breakdown." Laurie Laybourn-Langton, its lead author, told me via email: "I appreciated the frankness of the report in facing up to issues that so many in research and policy communities seem unwilling to. We don't subscribe to the view that social collapse is inevitable, however." He explains: "This is partly because it's so hard to predict the outcomes of the complex and uncertain process of environmental shocks interacting with social and economic systems. We simply don't know. That said, they shouldn’t be disregarded as a potential outcome, and so we are calling for greater levels of preparedness to these shocks." Not everyone was so taken with the paper. Bendell submitted it to a well-respected academic journal for publication, with little success. Sustainability Accounting, Management and Policy Journal (SAMPJ) told me that the paper was in need of "major revisions" before it would be ready for publication. Bendell ended up publishing it through IFLAS and his blog. "The academic process is such that I took that as an effective rejection," he explains, saying that the reviewers wanted him to fundamentally alter his conclusions. "I couldn't completely rewrite the paper to say that I don't think collapse is inevitable. It was asking for a different paper." Emerald, the scholarly publisher that owns SAMPJ, says it takes issue with how Bendell frames its reception of its paper on his blog: "the study on collapse they thought you should not read—yet." A spokesperson told me: "The decision was arrived at based on the merit of the submitted article and the double blind peer review process integral to academia and the advancement of knowledge. SAMPJ, and [editor Carol Adams] are proud members of the Committee on Publication Ethics (COPE) and adhere to the highest ethical standards in publishing. We see no evidence that the decision of Major Revision was politically motivated. "Emerald requested the author correct their blog post to reflect the facts. This request was unfortunately ignored. The post continues to imply the paper was rejected because it was deemed too controversial. The paper was not rejected, and was given a Major Revision due to the rigorous standards of the scholarly output of the journal." Bendell says he did reply to Emerald's request to amend his blog post—but only if they would consider telling him the decisions of those who reviewed his paper. (Under the double blind peer review, reviewers' decisions are anonymous.) "That title can be read in a number of ways," he says. "It is a paper that the reviewers didn't want you to read. They didn't want it published." Climate gloom and doom is nothing new—doomsday preppers have been stockpiling their freeze-dried food rations for decades now. But Bendell's paper appears to have hit a unique nerve, especially given that the average scientific paper is estimated to be read by only three or so people. Rupert Read tells me that he was sent it simultaneously by three other academics when it was published. But it hasn’t trended on Twitter. It hasn't been pushed by a celebrity. It was briefly mentioned in a Bloomberg Businessweek article, but that's it. "Deep Adaptation" is that unique social phenomenon: an academic paper that has gone viral through word of mouth. Nathan Savelli, a 31-year-old high school life coach from Hamilton, Canada, was recommended the paper by a local environmental activist. Reading it sent him spiraling into depression. "I guess in some ways it felt like I was diagnosed with a terminal illness," he tells me. "If I'm being honest, it was a mix of heartbreaking sadness and extreme anger." Savelli felt so low that he sought help from a climate grief support group organized by 350.org, the global grassroots climate movement. "I had attended counseling in the past for other issues, but never a group session, and thought it might be something helpful for me," he tells me. Did it help? "I'm not sure I'd say it alleviated my grief, but it was definitely comforting to be around people who understood what I was feeling." And therein lies the problem with "Deep Adaptation:" if you accept that the paper is entirely correct in its prediction of collapse, how do you move on with your life? How do you even get out of bed in the morning? "I'm aware of what difficult emotions it triggers," Bendell acknowledges. "I do believe that if you’ve come across this [paper], then absolutely some grief and despair is very natural. Why isn't that OK? We all die in the end. Life is about impermanence." On his blog, he lists several sources for psychological support, including several groups on Facebook and LinkedIn that discuss collapse and offer help to those struggling to come to terms with the conclusions of his paper. But, Bendell adds, reading the paper has been "transformative" for some. "People find a new boldness about living life on their own terms—actually connecting to their heart's desire. How do they wish to live, and why don't they live that way now rather than postponing it?" In one case, it even helped prompt one high-ranking academic to quit her job and the city. In December of 2017, Dr. Alison Green left her post as the pro vice-chancellor of Arden University. She had read the IPCC report warning that the world is nowhere near averting global temperature increases, as well as the 1,656-page National Climate Assessment on how climate change is now dramatically affecting our lives—and then she read Bendell's paper.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › Warming defense
Sebastian Farquhar 17 leads the Global Priorities Project (GPP) at the Centre for Effective Altruism, et al., 2017, “Existential Risk: Diplomacy and Governance,” https://www.fhi.ox.ac.uk/wp-content/uploads/Existential-Risks-2017-01-23.pdf
The most likely levels of global warming are very unlikely to cause human extinction.15 The existential risks of climate change instead stem from tail risk climate change – the low probability of extreme levels of warming – and interaction with other sources of risk. It is impossible to say with confidence at what point global warming would become severe enough to pose an existential threat. Research has suggested that warming of 11-12°C would render most of the planet uninhabitable,16 and would completely devastate agriculture.17 This would pose an extreme threat to human civilisation as we know it.18 Warming of around 7°C or more could potentially produce conflict and instability on such a scale that the indirect effects could be an existential risk, although it is extremely uncertain how likely such scenarios are.19 Moreover, the timescales over which such changes might happen could mean that humanity is able to adapt enough to avoid extinction in even very extreme scenarios. The probability of these levels of warming depends on eventual greenhouse gas concentrations. According to some experts, unless strong action is taken soon by major emitters, it is likely that we will pursue a medium-high emissions pathway.20 If we do, the chance of extreme warming is highly uncertain but appears non-negligible. Current concentrations of greenhouse gases are higher than they have been for hundreds of thousands of years,21 which means that there are significant unknown unknowns about how the climate system will respond. Particularly concerning is the risk of positive feedback loops, such as the release of vast amounts of methane from melting of the arctic permafrost, which would cause rapid and disastrous warming.22 The economists Gernot Wagner and Martin Weitzman have used IPCC figures (which do not include modelling of feedback loops such as those from melting permafrost) to estimate that if we continue to pursue a medium-high emissions pathway, the probability of eventual warming of 6°C is around 10%,23 and of 10°C is around 3%.24 These estimates are of course highly uncertain. It is likely that the world will take action against climate change once it begins to impose large costs on human society, long before there is warming of 10°C. Unfortunately, there is significant inertia in the climate system: there is a 25 to 50 year lag between CO2 emissions and eventual warming,25 and it is expected that 40% of the peak concentration of CO2 will remain in the atmosphere 1,000 years after the peak is reached.26 Consequently, it is impossible to reduce temperatures quickly by reducing CO2 emissions. If the world does start to face costly warming, the international community will therefore face strong incentives to find other ways to reduce global temperatures.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › China bills fail
Lizz Peek Feb 10 2022 "GOP: Don’t fall for the America Competes Act,"
But, back to the widely publicized core of the bill, which purports to boost semiconductor manufacturing at home. Legislators are concerned that the U.S., the birthplace of advanced silicon and once the dominant supplier of the widely used electronic components, only accounted for 12 percent of global production in 2020, down from 37 percent in 1990. Advocates neglect to mention that the U.S. has enjoyed a steady rise in chip output, and in investment.
This comes at a time when chips are in short supply, the industry consequently is operating full out and reaping record profits. After decades during which technology gains made chips cheaper and prices dropped, companies have been raising prices aggressively. TSMC announced last year that it would raise prices up to 20 percent, its largest hike in a decade. Other companies have done the same, with the prices of some chips soaring as much as 40 percent.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › China bills fail
Tom Lee Feb 1 2022 "Industrial Policy: America COMPETES Act and USICA" https://www.americanactionforum.org/insight/industrial-policy-america-competes-act-and-usica/
While CHIPS is very popular on both sides of the aisle, it may not relieve current shortages as intended. It takes many years to build a physical semiconductor production facility, so by the time CHIPS became law and it funds were spent on building production facilities in the United States, the COVID-19-induced global semiconductor shortage would be over. Moreover, the semiconductor industry, like many other capital-intensive industries, is cyclical in nature because it is logistically difficult and expensive for manufacturing facilities to rapidly increase production to meet sudden surges in demand. It is thus best for market mechanisms, not government intervention, to address these issues.
The private sector is already making its own investments (with no federal funding) that are far larger than the $52 billion funding in CHIPS. Intel has announced plans to invest $20 billion into two semiconductor factories in Ohio.[3] TSMC, a Taiwanese company and one of the largest producers of semiconductors, has announced plans to spend $12 billion on a new production facility in Arizona.[4] Micron will spend $150 billion over the next 10 years to build new production facilities in the United States.[5] Samsung has also announced plans to invest $17 billion in a new production facility in the United States. These private-sector projects alone would invest nearly $200 billion, and all were announced before CHIPS. The $52 billion in CHIPS spending is an arguably unnecessary intervention, which would benefit a largely healthy semiconductor industry.[6]
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › Political Capital Fails
Dr. George C. Edwards 2016 III, Distinguished Professor of Political Science and Jordan Chair in Presidential Studies at Texas A&M, “The Potential of Presidential Leadership”, Study Done for the White House Transition Project https://www.whitehousetransitionproject.org/wp-content/uploads/2020/10/WHTP2021-08-Potential-of-Presidential-Leadership.pdf
The best evidence is that presidential persuasion is effective only at the margins of congressional decision making. Presidential legislative leadership operates in an environment largely beyond the president’s control and must compete with other, more stable factors that affect voting in Congress in addition to party. These include ideology, personal views and commitments on specific policies, and the interests of constituencies. By the time a president tries to exercise influence on a vote, most members of Congress have made up their minds on the basis of these other factors.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › Political Capital Fails
Ryan Telingator B.A. in Political Science and Government from Bowdoin University, May 20 2021, “When is Change Possible? Presidential Power as Shaped by Political Context, Constitutional Tools, and Legislative Skills”, https://digitalcommons.bowdoin.edu/honorsprojects/258/
My research does not support Greenstein’s theory. Instead, my findings align more closely with those of George Edwards in At the Margins, where he argues that the “national preoccupation with the chief executive is misplaced,” and that presidential power is, in fact, limited in the Constitution’s “purposefully inefficient system in which the founding fathers’ handiwork in decentralizing power defeats even the most capable leaders.”50 Instead of focusing on legislative skills as a source of presidential influence, Edwards argues that party support and public support are more important. Legislative skills are only critical for “members of Congress who remain open to change after other influences have had their impact.”51 In a time as polarized as today, where very few members of Congress are “open to chang[ing]” their vote, these skills play a minor role in legislative negotiations. Similar assertions are made in another book by Edwards, Predicting the Presidency. He argues that exploiting existing opportunities (consolidating existing party and public support) is much more important for presidential success than creating opportunities (convincing legislators to change their vote vis a vis legislative skills).52 Both Lyndon Johnson and Ronald Reagan are remembered for their exemplary political skills. The Johnson Treatment, a legislating strategy in which Johnson used his imposing 6’4”, 240-pound figure – literally physically and verbally bullying, cajoling, lobbying, and threatening – to get what he wanted out of people,53 remains infamous in presidential political literature. Similarly, Ronald Reagan, “The Great Communicator,” is still revered for his oratorial prestige. Although these legislative skills were useful in passing the pieces of legislation outlined in the case studies – Johnson gaining support from southern Democrats on the EOA and Reagan compellingly speaking in favor of the ERTA – they proved impotent in political contexts not conducive to change. After Vietnam for Johnson and after the passage of the ERTA for Reagan (in conjunction with the recession in 1982), the presidents’ policy windows closed. Their renowned legislative skills could not overcome an inopportune political context. The case studies thus demonstrate the value of skills at the margins, but also exemplify their unsubstantial influence as the major factor driving policy. Again, the research suggests that political context is the most important factor in legislative change. 5.4 Applying Lessons to the Present: Predicting Biden’s Success With an understanding that the political context largely drives a president’s potential for change, with skills helping on the margins, it is important to assess the 2021 political climate in order make an informed prediction about Biden’s prospects. The COVID-19 pandemic opened a significant policy window for Biden. With a U.S. death toll nearing 580,000, massive unemployment, and a severe economic contraction, the pandemic was an all-encompassing problem that the entire country wanted addressed. Thus, the three streams of problem, policy, and politics converged to open the opportunity for the Biden administration to pass the American Rescue Plan. The Rescue Plan was signed into law in March and has received bipartisan support from the American public.54 President Biden claimed a mandate from his election, arguing that “millions of Americans” “voted for [his] vision,” giving “a clear victory” and tasking him to make his “vision real.”55 However, based on the extreme polarization in D.C., it is unlikely to become a quantifiable mandate that changes Congressional voting behavior.56 Polarization has made it impossible to win cross-party support, or, in Edwardsian terms, create new opportunities. There is deep political antagonism between parties, and even within parties,57 making any sort of bipartisanship near impossible.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › Winners win
Phil Mattingly 2021, “Biden wanted to remind Democrats what it was like to win. Now he's aiming to capitalize on that momentum.,” CNN, 11-9-2021, https://www.cnn.com/2021/11/09/politics/joe-biden-infrastructure-bill-momentum/index.html
When President Joe Biden worked the phones for hours late into Friday night to push through his massive infrastructure bill, what he really wanted was to show Democrats what it felt like to win. After months of missed deadlines, simmering distrust and political fallout, White House officials now hope success can breed success. The victory came at a critical moment for a party and a President mired in months of internecine legislative warfare that had largely overshadowed the actual policies in question. Getting the $1.2 trillion package over the line is viewed by the White House and its Democratic allies as a moment where some trust -- however fragile -- has been established between the party's different factions, giving Democrats the chance to finally turn the corner. "It helps when you succeed on something and everybody sees and figures out what it feels like to win and get something done," a senior administration official said. "It creates momentum." "Momentum" is hardly a scientific concept, and there aren't any misconceptions inside the West Wing about the complicated high-wire act required in the weeks ahead to clinch the $2 trillion economic and climate package that makes up the second piece of Biden's domestic agenda, officials say. But the hours of frenzied Friday night negotiations, in close coordination with House Speaker Nancy Pelosi, led to something that has been missing throughout weeks of fits and starts, missed deadlines and delicate balancing act between moderates and progressives: An outcome. Biden is planning to capitalize on that victory by inviting scores of lawmakers to the White House for a formal signing ceremony next week, officials say. It's the type of event where eager members of Congress angle for a photo-op or signing pen -- something that has remained out of reach on Biden's central agenda items until now. In isolation, it doesn't resolve the existing policy divides facing Democrats on both sides of Pennsylvania Avenue on the second piece of Biden's agenda. But it does give lawmakers, who for months have clashed over the direction of the bills, something to celebrate -- and sell back home. "Now comes the hard part," one House Democrat told CNN early Saturday morning. It was a sentiment largely echoed by more than a dozen participants in the process throughout the weekend. But if the need to reconcile a series of policy thickets remains, there is a sense that the party dynamics may have, in fact, shifted in the frenzied final late-night hours that cleared the way to pass Biden's $1.2 trillion infrastructure proposal. "You see that whatever the things that are dividing you or separating you, it helps to clarify that actually we agree on a hell of a lot more," the official said. That process, arduous and painful as it may have been -- both politically and in terms of the caucus dynamics -- finally led to a breakthrough. Now that breakthrough needs to translate into action on the broader and more transformational economic and climate package. That's exactly what White House officials are banking on. "It ain't over yet as they say the old expression goes, but I feel good," Biden told reporters on Monday after an event celebrating the defending NBA Champion Milwaukee Bucks. "I think people have realized, are beginning to realize it's important to get it done." Biden draws a line in the sand The agreement drove the players leading those clashes together to reach a deal, culminating in a massive piece of legislation passing the House. In a party driven -- in the words of one House Democrat -- "not by mistrust, but by no trust," it was an important development. It also came at a critical moment for Biden, with his poll numbers sitting at their lowest point of his first year in office and just days after Democrats emerged from an election night that saw their nominee for governor in Virginia -- a state Biden won by 10 points just one year ago -- lose. "I think the one message that came across was: Get something done," Biden told reporters of the role in the Virginia governor's race in the outcome. "It's time to get something done. " Biden, who for weeks took quiet criticism from House Democrats for not publicly drawing a harder line on what he wanted, pivoted hard to do exactly that during those final hours -- something Pelosi explicitly called for, people involved told CNN. But reaching that point was a progression, officials said, developed over months of negotiations, private conversations, blown deadlines, intraparty recriminations and -- in some cases -- what many Democrats viewed as missed opportunities. It was, for better or worse, all part of the process for a new administration and congressional Democrats adjusting to full control in Washington for the first time in decade. "It's getting to know a lot of these people, to build trust," Biden told reporters the day after the bill passed. "Because everything I say I'm going to try to do, I will try to do. And I think that's also part of the process." A Senate veteran learns more about the House Biden's point is a window into the last several months, where a 36-year veteran of the Senate -- who often makes clear in private settings his view that he has an innate sense for Capitol Hill -- faced his own learning curve, particularly in the House. The party dynamics have shifted, with progressives carrying not just a voice, but the votes to dictate what will or won't advance. Many came to office in the four years after Biden left Washington. Even more had never served in the majority with a Democratic president. Exacerbating it all were the barest of majorities in the House and Senate, making Biden's ambitious policy agenda -- which progressives overwhelmingly supported -- even more complicated to advance. Biden has sought to reintroduce himself to the dynamics by hosting scores of lawmakers in the Oval Office, crowding lawmakers onto couches and hearing them out over the course of dozens of meetings since taking office. While each meeting usually has an officially stated purpose, they have served more generally as get-to-know-you sessions, during which Biden is able to gain greater insight into each member's particular needs. For many, it is their first visit to the White House; Biden's predecessor Donald Trump did not habitually invite Democrats to meet with him. They often leave with White House-baked chocolate chip cookies or, more recently, specially commissioned ice cream bars bearing Biden's presidential seal. A lightning-fast, at least by congressional standards, win on Biden's $1.9 trillion Covid-19 relief proposal in his first few months in office was -- to a degree -- misleading. The urgency mattered, with the country still mired in the worst of the pandemic. Democrats were exceedingly careful not to undercut their new president -- or their new Senate majority. The path on his $3 trillion, dual-pronged domestic agenda has been significantly less seamless. Even for the self-professed "congenital optimist" in the Oval Office, navigating the divides has proved frustrating in recent weeks as his negotiators and Democratic leaders sought to thread the needle through compromises and self-imposed deadlines, to no avail. "We have to develop the will, and develop the will means putting aside personal agenda," Rep. Jim Clyburn, the House Democratic whip form South Carolina and a close Biden ally, said on "Fox News Sunday." "That to me has been a problem for us." It also takes a recognition that any single member can create a new problem to resolve. Those problems appeared to perpetually win the day -- until late Friday night. "This, in terms of degree of difficulty is very, very high," the official said. "Which makes succeeding all the more satisfying and fulfilling." Working the phones Still, the plans for that victory were quickly thrown off track Friday morning by a small group of House moderates who refused to move forward without a full Congressional Budget Office accounting of whether the second package would be financed. With that off the table for at least a week and maybe longer, Pelosi shifted course. The decision to move the infrastructure bill without the second proposal, pitched by members of the Congressional Black Caucus and moved on by Pelosi, initially ran into the same progressive roadblock that had sidetracked the prior two deadlines. But unlike those moments -- when Biden was regularly on the phone with members but cautious not to corner or jam any member -- the President went all in to find a path forward, according to people familiar with the calls. He and his team worked in close coordination with Pelosi on who to call and what to float as potential options to reconcile the differences. The two spoke by phone four times, with Pelosi giving Biden names of lawmakers to call and working closely with his top negotiators as they worked through the process of laying the groundwork to move forward. Biden made calls to moderate members. He made calls to progressive members. He talked to most of Pelosi's leadership team over the course of the day. It wasn't immediately effective. Biden was explicitly told "no" in a call with at least one progressive -- Rep. Pramila Jayapl, the chair of the Congressional Progressive Caucus -- sources said. Jayapal initially rejected the effort publicly as well. In a conference call with dozens of progressives, there was palpable frustration on Biden's part when the reticence to move forward on infrastructure without the second proposal was made clear, according to participants. An official acknowledged that some of the conversations "were a little bumpy" and not everyone was on board at the beginning. But the decision was made to continue to press forward. The result -- after hours of calls, negotiations, an official statement from Biden -- was progressive and moderate leaders coming together to craft statements committing to move forward on the economic and climate package once the CBO score was in hand.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › Winners win
Paul Kane 2021, Senior Congressional Correspondent and Columnist at the Washington Post, “Day-to-day, Biden’s Agenda Looks Rocky. But Congressional Democrats Say Things Are Far Rosier If You Take The Long View.”, Washington Post, 7/24/2021, https://www.washingtonpost.com/powerpost/biden-agenda-democrats-congress/2021/07/24/83b776be-ebc0-11eb-ba5d-55d3b5ffcaf1_story.html
There is, so far at least, little fear that Democrats are spreading themselves too thin by eschewing the traditional practice of focusing on a handful of domestic policy issues in the first two years of an administration. “Political momentum and political capital is like a muscle. The more you exercise it, the more of it you have. It is not like a finite resource that you can run out of if you spend too much of it. What happens is that if we do a lot of positive things, then we’ve got more political clout to do even more positive things,” Sen. Brian Schatz (D-Hawaii) said.
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › PC Spent Already
Joseph Clark March 22 2022 The Washington Times, “China competition bill set to advance to final negotiations in Congress after months of delays”, https://www.washingtontimes.com/news/2022/mar/22/china-competition-bill-set-advance-final-negotiati/
The has forged ahead with a long-stalled bill to promote U.S. production of microprocessor chips to better compete with China, preparing to inch the legislation forward and into a tough round of negotiations with the . President Biden has pressed Congress for quick passage of the sweeping legislation but key differences remain between the and versions. The version is the $250 billion U.S. Innovation and Competition Act. The counterpart is the $335 billion America COMPETES Act. After months of stalls, Majority Leader Charles E. Schumer set up the votes to get the legislation into a bicameral conference committee to begin reconciling the two bills. “This legislation has been dissected and debated for well over a year now,” Mr. Schumer, New York Democrat, said on the floor Tuesday. “But the need to pass this bill really boils down to two simple words: J-O-B-S, jobs and C-O-S-T-S costs.” Both the and versions include a $52 billion boost for semiconductor manufacturing to combat a chip shortage. “There’s nothing abstract about the shortage of chips,” Mr. Schumer said. “It impacts Americans’ abilities to buy cars, refrigerators, phones, and other household items. By passing bipartisan legislation that invests in domestic chip production, we can help alleviate this vexing chips crisis.” The version first passed in June with the support of 18 Republicans and 50 Democrats. But the nearly 3,000-page version also includes a hodgepodge of spending including $8 billion to help developing countries address climate change, funding to make the U.S. less reliant on Chinese solar technology and $45 billion to shore up U.S. supply chains. House Republicans railed against the bill, which passed 222 to 210 last month, as a “foreign policy failure” that funnels taxpayer dollars into an “unaccountable U.N. slush fund” without addressing threats to U.S. national security posed by China. Republicans also voiced frustration with the process, saying they were sidelined while Democrats wrote the bill. Sen. Todd Young, an Indiana Republican who worked on the version, said he is committed to making the final bill more palatable for Republicans. The bill is a priority for Democrats and its passage would be a big win for Mr. Biden, who has been hobbled by a string of legislative defeats. Mr. Biden also has struggled to untangle a global supply chain hobbled by shipping delays and backlogs. And, the U.S. has been edged out of semiconductor manufacturing in recent decades by overseas producers. On Monday, Commerce Secretary Gina Raimondo urged lawmakers to quickly move the legislation through Congress. “The situation as it relates to semiconductors is quite dire,” Ms. Raimondo said in a call with senators of both parties. Ms. Raimondo brought in former Trump administration officials, for the call including former national security adviser H.R. McMaster, to help sway lawmakers. During the call, Mr. Young said he welcomed the start of formal negotiations between the and but wanted an open process “with input from all of my colleagues and consistent with what we call around here regular order.” “I know the vote will not be unanimous and that both parties and members of both parties are going to have to make principled compromises, principled concessions, in order to get an agreement done,” he said. “That’s always what happens when you approach a negotiating table. But America and the world will be better off with a bipartisan, broadly supported final product.”
2022
SDI
Disadvantage
MSDI Politics – China › Affirmative Answers › Thumpers
AMIE PARNES - 06/21/22 9:28 PM ET Biden expected to urge Congress to temporarily suspend gas tax https://thehill.com/homenews/administration/3532170-biden-expected-to-urge-congress-to-temporarily-suspend-gas-tax/
President on Wednesday is expected to call on Congress to temporarily suspend the gas tax during the summer months, according to sources familiar with the plan. Biden will ask that Congress assist in lifting the 18 cent tax per gallon on regular gasoline during the busy summer months, a source said. The White House has been weighing a recommendation on a federal gas tax holiday for the past week, The Hill first reported, as gas prices topped $5 per gallon on average nationally. Already high gas prices have been exacerbated by Russian President war in Ukraine.